|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression multiple interactions |
ISO |
cobimetinib results in increased expression of BCL2L11 protein; cobimetinib results in increased expression of BCL2L11 protein alternative form 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein alternative form]; 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased expression of BCL2L11 protein]; [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine co-treated with cobimetinib] results in decreased phosphorylation of BCL2L11 protein alternative form; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of BCL2L11 protein alternative form] |
CTD |
PMID:22084396 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
multiple interactions increases response to substance |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [BRAF protein mutant form results in increased susceptibility to cobimetinib] |
CTD |
PMID:22084396 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
cobimetinib results in decreased expression of CCND1 protein 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in decreased expression of CCND1 protein] |
CTD |
PMID:22084396 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
EXP |
cobimetinib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases response to substance multiple interactions |
ISO |
KRAS protein mutant form results in increased susceptibility to cobimetinib 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [KRAS protein mutant form results in increased susceptibility to cobimetinib]; cobimetinib promotes the reaction [KRAS protein mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] |
CTD |
PMID:22084396 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
ISO |
cobimetinib results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:22084396 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
ISO |
cobimetinib results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:22084396 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
increases response to substance |
ISO |
NRAS protein mutant form results in increased susceptibility to cobimetinib |
CTD |
PMID:22084396 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [cobimetinib results in increased cleavage of PARP1 protein]; cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased cleavage of PARP1 protein] |
CTD |
PMID:22084396 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
cobimetinib promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:22084396 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|